PT-141
Bremelanotide · Vyleesi
Last updated
At a glance
Overview
PT-141 occupies a specific corner of the bodybuilding and looksmaxxing toolkit: it's the one libido tool that works upstream of hormones and blood flow. Because it activates MC4R in the hypothalamus rather than relaxing smooth muscle downstream, it fires even when sildenafil and tadalafil don't — in PDE5 non-responders, in AAS users with crashed or over-aromatized E2, in guys on 5-AR inhibitors with suppressed DHT, and in anyone whose SSRI has flattened dopaminergic arousal.
The community tends to treat PT-141 as libido insurance: a PRN subcutaneous injection used on the 1–3 nights per week when desire needs to be guaranteed, usually stacked with daily low-dose tadalafil so the central (arousal) and peripheral (erection quality) pathways are both covered. It is emphatically not a pre-sex compound in the sildenafil sense — onset is 2–6 hours, peak is slow, and the smart move is usually to dose the evening before or early in the day.
"ED subjects who did not respond to sildenafil showed a significant erectile response to SC PT-141, particularly at doses of 4 and 6 mg." — Rosen et al., Int J Impot Res (2004)
The rest of this page covers the dose ladder (0.25 mg beginner test through 1.75 mg standard, with a hard ceiling around 2 mg), reconstitution and SC injection technique, how to time it around sexual activity, nausea and BP mitigation, the stacking logic with tadalafil and cabergoline, and the contraindications that actually matter — uncontrolled hypertension, cardiovascular disease, and any personal or family history of melanoma or dysplastic nevi.
How PT-141 works
PT-141 (bremelanotide) is a cyclic 7-amino-acid analog of α-MSH, structurally derived from Melanotan-II. Unlike every other sexual-function compound in the toolkit, it works centrally — inside the brain — rather than on the penile vasculature. That single fact drives everything downstream: why onset is slow, why it works in PDE5 non-responders, why nausea and flushing are the dominant side effects, and why it pairs so cleanly with tadalafil rather than competing with it.
Central MC4R Agonism (the primary lever)#
PT-141 is a non-selective melanocortin receptor agonist with its functionally relevant activity at MC4R, and secondary activity at MC3R and MC1R. It crosses the blood–brain barrier and binds MC4R on hypothalamic neurons — particularly in the medial preoptic area (mPOA) and paraventricular nucleus (PVN), the two nodes that govern sexual motivation and the autonomic output that produces erection and lubrication.
"PT-141 acts centrally, activating melanocortin receptors in the CNS, specifically the MC4 receptor… producing prosexual effects upstream of nitric oxide and PDE5 inhibition." — Molinoff PB et al., Annals of the New York Academy of Sciences, 2003
The practical consequence: PT-141 triggers desire and arousal, not just erectile hardness. This is why it works for women (the on-label HSDD indication) and for men whose problem isn't mechanical but motivational — SSRI-blunted libido, crashed-E2 on cycle, post-AAS anhedonia, psychogenic ED.
Dopaminergic Drive in the mPOA#
MC4R activation on mPOA neurons triggers dopamine release into the surrounding circuitry — and dopamine in the mPOA is the proximate neurochemical trigger for sexual arousal in both sexes.
"Bremelanotide facilitates sexual motivation, arousal, and partner preference in animal models by increasing dopamine release in relevant hypothalamic circuits." — Pfaus JG, Giuliano F, Gelez H, The Journal of Sexual Medicine, 2021
This is the mechanistic reason PT-141 rescues SSRI-induced sexual dysfunction: SSRIs suppress dopaminergic tone in exactly this circuit, and PT-141 drives it back up without requiring you to taper the SSRI. It's also why PT-141 restores libido in AAS users with mismanaged estrogen — the compound operates downstream of whatever hormonal mess is going on, as long as the circuitry is intact.
Upstream of the NO/cGMP Axis (why it stacks with tadalafil)#
PDE5 inhibitors (sildenafil, tadalafil) work peripherally: they inhibit cGMP breakdown in penile smooth muscle, amplifying the nitric oxide signal that produces vasodilation and erection. They do nothing for desire. PT-141 is the mirror image — it drives the central signal that initiates the erectile cascade in the first place, but doesn't directly affect cavernosal smooth muscle.
Because the two mechanisms are orthogonal, they stack additively:
"The combination of low-dose PT-141 and sildenafil produced a significantly greater erectile response than either agent alone." — Diamond LE et al., Urology, 2005
And because PT-141 bypasses the NO/cGMP pathway entirely, it works in men who get nothing from PDE5 inhibitors alone:
"ED subjects who did not respond to sildenafil showed a significant erectile response to SC PT-141, particularly at doses of 4 and 6 mg." — Rosen RC et al., International Journal of Impotence Research, 2004
For the bodybuilding / looksmaxxing audience, the practical stack is tadalafil 5 mg daily (peripheral hardness + pump + BP management on cycle) + PT-141 1.5–1.75 mg PRN (central desire). This is the canonical libido-rescue protocol during late cycle, PCT, or HPTA recovery.
PK/PD Disconnect (why onset is 2–6 hours, not 30 minutes)#
PT-141's plasma half-life is only ~2 hours after subcutaneous injection, with Cmax around 60 minutes — but the subjective effect typically peaks 2–6 hours post-dose and pharmacodynamic activity lasts 8–24+ hours. The rate-limiting step isn't getting peptide into circulation; it's the downstream cascade of MC4R activation, dopamine release, and autonomic pre-loading in the hypothalamus. Receptor-level effects outlast plasma levels considerably.
Translation for dosing: PT-141 is not a 30-minute compound. Inject 4–8 hours before anticipated activity, or dose the night before. Users who slam it 20 minutes pre-sex conclude it doesn't work; the actual window hasn't opened yet.
Off-Target Melanocortin Activity (the side-effect profile)#
The side-effect profile is a direct readout of PT-141's other receptor targets:
- MC1R (cross-activation) → the same receptor Melanotan-II hits on melanocytes. Produces mild skin darkening, freckling, and nevus intensification with frequent dosing. This is the mechanistic reason for the hard contraindication in users with dysplastic nevi or melanoma history, and why stacking PT-141 with full-dose MT-II is not recommended — overlapping melanocortin agonism compounds the pigmentation and nevus risk.
- MC3R / MC4R central effects → nausea (the dominant complaint, worst in the first 30–90 min), flushing, appetite suppression, and a transient dose-dependent BP rise of roughly 6 mmHg systolic peaking 2–4 hours post-dose. This BP effect is why the intranasal formulation (higher Cmax) was abandoned, and why uncontrolled hypertension is a hard contraindication — if you're already running 145/95 on cycle, fix BP before adding PT-141.
Everything PT-141 does — the good and the bad — traces back to melanocortin receptor agonism. Keeping dosing intermittent (1–3× weekly ceiling, PRN only) keeps the sexual benefits dialled in while minimizing the MC1R pigmentation drift and tachyphylaxis that show up with near-daily use.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.25–0.5 mg | As needed | Documented entry-level range |
| Mid | 1–1.75 mg | As needed | Most commonly studied range |
| High | 1.75–2 mg | As needed | PRN only, 4–8 hours before anticipated activity (onset is central and slow — not a 30-minute compound). Max 1 dose per 24h, ceiling of 1–3× per week to avoid tachyphylaxis and pigmentation. Doses above 2mg rarely improve effect and sharply increase nausea. |
Cycle length & outcomes
Cycle Structure#
PT-141 isn't cycled in the traditional sense — there's no HPTA suppression, no receptor downregulation requiring a washout, and no PCT. It's a PRN (as-needed) compound, and the "cycle" is really a frequency cap to avoid tachyphylaxis and MC1R-mediated pigmentation.
| Use Case | Frequency | Dose per Session |
|---|---|---|
| First-time test dose | Single dose, evening | 0.25–0.5 mg SC |
| Occasional libido rescue (on-cycle / PCT) | 1–2× per week | 1.0–1.75 mg SC |
| PDE5 non-responder protocol | 1–3× per week | 1.75 mg SC (± sildenafil 50 mg) |
| Female partner HSDD (Vyleesi label) | ≤1 dose/24h, ≤8 doses/month | 1.0–1.75 mg SC |
| Experienced ceiling | Not more than 3× per week | 1.75–2.0 mg SC |
Onset & Timing#
The single most common mistake is treating PT-141 like sildenafil. It isn't. Plasma Tmax is ~1 hour, but subjective onset is 2–6 hours post-injection because the rate-limiting step is central MC4R activation and downstream dopaminergic signalling, not plasma concentration.
"PT-141 acts centrally, activating melanocortin receptors in the CNS, specifically the MC4 receptor… producing prosexual effects upstream of nitric oxide and PDE5 inhibition." — Molinoff et al., Ann N Y Acad Sci (2003)
Two practical timing strategies work well:
- Evening dose, morning effect: inject 1.0–1.75 mg SC around 9–10 pm, sleep through the nausea window, wake up with elevated desire and easier erections lasting through the morning.
- Afternoon dose, evening effect: inject 4–6 hours before anticipated activity. Eat lightly 30 min before dosing; heavy meals don't blunt effect but can worsen nausea.
The FDA label for Vyleesi specifies "at least 45 minutes" pre-activity — that's the minimum, not the optimum. Pharmacodynamic duration runs 8–24 hours in practice, well beyond the 2-hour plasma half-life.
No Loading, No Tapering#
There is no loading phase, no titration schedule required for efficacy, and no taper on discontinuation. The only reason to "titrate" is tolerance of nausea — start at 0.5 mg, confirm you tolerate it, then move to the 1.0–1.75 mg working range.
Stacking Windows#
- With daily tadalafil 5 mg: run tadalafil continuously on cycle; layer PT-141 PRN on top. The two mechanisms are orthogonal — central desire/arousal versus peripheral NO/cGMP — and combine additively.
"The combination of low-dose PT-141 and sildenafil produced a significantly greater erectile response than either agent alone." — Diamond et al., Urology (2005)
- With cabergoline (0.25 mg 2× weekly) for nandrolone/trenbolone runners: cab fixes elevated prolactin at the source, PT-141 handles acute libido events while cab takes 2–4 weeks to fully work.
- Avoid stacking with Melanotan-II at full doses. Both are melanocortin agonists — overlapping MC1R activation accelerates pigmentation and stacking MC4R load increases nausea and BP response. If both are used, separate them by at least 24 hours and keep MT-II in maintenance mode.
Monitoring Cadence#
No routine bloodwork is triggered by PT-141 itself. The only practical monitoring is a home BP cuff — check sitting BP one hour pre-dose and 3–4 hours post-dose for your first 2–3 sessions, especially if you're already running AAS with any BP elevation. Expect a transient ~6 mmHg systolic rise peaking at 2–4 hours and resolving within 12.
"Bremelanotide 1.75 mg was effective in improving sexual desire and reducing distress in premenopausal women with HSDD, with the most common adverse event being nausea." — Kingsberg et al., Obstet Gynecol (2019)
Duration of Use#
There's no defined "cycle length" cap — PT-141 can be used indefinitely at PRN frequency. The practical limits are:
- Tachyphylaxis: response attenuates with daily or near-daily dosing. Keep usage ≤3× per week and the effect stays consistent for years.
- Pigmentation: focal darkening of face, gums, and new nevi builds slowly with frequent dosing. At ≤2× per week this is essentially a non-issue; at daily dosing over months it becomes visible.
- Skin surveillance: if you're running PT-141 regularly for more than 6 months, a baseline dermatology skin check is sensible — same logic as Melanotan-II. Do not use if you have personal or strong family history of melanoma or multiple atypical nevi.
Results are immediate per-dose rather than cumulative — you don't need 7–10 days of consistent dosing to "feel it." Either the dose worked this evening or it didn't, and if it didn't, the variables are timing, food, and dose size, not cycle length.
Risks & mistakes
Common (most users)#
- Nausea — the universal complaint and the main dose-limiter. Worst 30–90 minutes post-injection, usually fades before the subjective onset hits. Mitigate by: dosing before bed (sleep through it), pre-dosing ondansetron 4–8 mg 30 minutes prior, eating a small low-fat meal before injecting, and titrating up from 0.5 mg rather than jumping to 1.75 mg on the first run.
- Flushing — face and upper chest, harmless, resolves on its own. Don't dose before you have to be in public within the first 2 hours.
- Headache — frontal, usually mild. 400 mg ibuprofen handles it. If it's consistent at 1.75 mg, drop to 1.0–1.5 mg.
- Transient BP rise — ~6 mmHg systolic on average, peaking 2–4h post-dose and resolving inside 12h. Home cuff at baseline and 3–4h post-dose for your first couple of runs.
- Injection-site reactions — mild redness, itch, transient welt. Rotate abdomen and delt sites, swirl don't shake, use a fresh 29–31G insulin pin.
"Bremelanotide 1.75 mg was effective in improving sexual desire and reducing distress in premenopausal women with HSDD, with the most common adverse event being nausea." — Kingsberg et al., Obstet Gynecol 2019 (RECONNECT)
Uncommon (dose-dependent or individual)#
- Severe nausea / vomiting — almost always a dose issue. If 1.75 mg puts you on the floor, 1.0 mg is your dose. Chasing higher numbers rarely improves the subjective effect.
- Sustained BP elevation — if your 3–4h post-dose reading is consistently >15 mmHg above baseline, or you're already on-cycle with elevated BP, stop and fix the underlying hypertension (tadalafil 5 mg daily, telmisartan, cardio, sodium) before running PT-141 again.
- Skin hyperpigmentation / new freckles — MC1R cross-activation. Shows up with frequent dosing (>2×/week for months). Face, gums, and existing nevi darken first. Largely reversible on cessation but can take months. Keep dosing PRN at ≤2×/week and this is a non-issue.
- Darkening of existing moles — get a baseline skin check if you plan to run it more than occasionally, and photograph any nevi you're watching.
- Appetite suppression — MC3/MC4 effect, usually transient. Annoying on a lean bulk, useful on a cut. Not something to plan around.
- Spontaneous erections / priapism-adjacent events — at higher doses (>2 mg) or when stacked with a full-dose PDE5i. An erection lasting >4 hours is a medical emergency; anything over 90 minutes unwanted is a signal to drop the dose or separate the stack.
- Tachyphylaxis — response attenuates with frequent use. If the effect is fading, you're dosing too often, not too low. Pull back to 1×/week for a month.
Rare but serious#
- Hypertensive urgency — symptomatic BP spike with chest pain, severe headache, visual changes, or confusion. Stop, present to an ER, disclose the peptide. More likely in users who were already hypertensive at baseline.
- Focal cardiac events in users with pre-existing CAD — the BP/HR shift is small in healthy populations but not trivial in diseased vasculature. If you have a cardiac history, this isn't your compound.
- Melanocytic transformation — theoretical but taken seriously in the looksmaxxing community given melanocortin agonism. Any rapidly changing, asymmetric, or bleeding nevus → dermatologist, full stop, discontinue.
- Severe allergic / injection reaction — rare for a peptide of this size but possible. Widespread urticaria, facial swelling, or wheeze means epinephrine and ER, not "push through it."
Hard contraindications#
- Known cardiovascular disease — CAD, recent MI, stroke, unstable arrhythmia. The BP response is predictable and not worth the risk profile.
- Uncontrolled hypertension — fix the BP first. Running PT-141 on top of untreated 150/95 is the one scenario where this compound is genuinely dangerous.
- Personal history of melanoma, or multiple atypical/dysplastic nevi — do not run PT-141. Same rule as melanotan-II.
- Pregnancy or active attempts to conceive (female partner dosing) — animal reproductive toxicity data; off the table until after delivery and breastfeeding.
- Concurrent oral naltrexone — PT-141 reduces naltrexone AUC significantly. If you're on naltrexone for anything that matters (AUD, LDN protocol), don't stack.
- Co-administration with full-dose melanotan-II — overlapping melanocortin agonism stacks the pigmentation, nausea, and BP effects with no gain in sexual response. Run one or the other, not both at full dose simultaneously.
- "30 minutes before sex" dosing expectation — not a contraindication, but worth stating plainly: onset is central and slow, 2–6 hours. If you treat it like a PDE5i you will be disappointed and over-dose chasing an effect that hasn't arrived yet.
Gender, stacking, and PCT notes#
PT-141 is non-hormonal, non-suppressive, and PCT-neutral — no impact on HPTA, LH/FSH, E2, prolactin, lipids, or liver enzymes. It stacks freely with AAS, SARMs, GH, insulin, and the rest of the toolkit. No virilization risk for women; it's literally the FDA-approved HSDD drug in that population, with female partners typically tolerating 1.0 mg better than the 1.75 mg label dose at similar subjective effect.
For on-cycle users, the only practical monitoring is a home BP cuff — bloodwork you're already running (CMP, lipids, hormones) doesn't need to change because of PT-141. For post-cycle and PCT users, PT-141 + tadalafil 5 mg daily is the cleanest libido bridge while the HPTA comes back online; neither compound interferes with SERM-based recovery.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.00 | ×1.00 | ×1.10 | |
| synergistic | ×1.00 | ×1.00 | ×1.00 | |
| synergistic | ×1.00 | ×1.00 | ×1.00 |
Pharmacokinetic conflicts, competing pathways, or compounded toxicity. Multipliers below 1 indicate the affected axis.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| antagonistic | ×1.00 | ×1.00 | ×0.90 |
Featured in stacks1 curated protocol include PT-141
FAQ — PT-141
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy PT-141 (Bremenalotide), 10mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy PT-141
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- PT-141 (Bremelanotide)Buy PT-141
Research & citations
5 studies cited on this page.
Conclusion
PT-141 is the go-to libido rescue tool when on-cycle, post-cycle, or SSRI use has shut down sexual desire — central action, fast onset, and no dependence on E2 or DHT.
Key takeaways:
- Standard SC dose: 1.0–1.75 mg PRN, inject 4–8 hours before activity (not a 30-min pre-game shot)
- Start at 0.25–0.5 mg to assess nausea and BP response before titrating up
- Mechanism is central MC4R agonism — works for libido/arousal even when PDE5 inhibitors fail (Molinoff 2003, Rosen 2004)
- Stacks cleanly with tadalafil/sildenafil (mechanisms are additive) for both desire and performance (Diamond 2005)
- Nausea and flushing are common but mitigatable with slow titration and ondansetron; keep total use to ≤2×/week to avoid tachyphylaxis and hyperpigmentation
- Hard contraindications: uncontrolled hypertension, melanoma or atypical nevi history, do not combine with naltrexone
If you want a true on-demand desire boost — as a standalone or with PDE5s — PT-141 is the community-standard choice for central arousal that brute-forces libido when nothing else does.